poisar

Stocks · News reference

Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target

Benzinga Newsdesk

Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform and maintains $40 price target.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DMRA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Damora Therapeutics granted equity awards to five newly-hired non-executive employees on October 1, 2026, consisting of options to purchase 144,400 ordinary shares at $21.28 per share with a 10-year term. The inducement grants were approved by the Compensation Committee as material incentives for employment acceptance.

    DMRA
  3. Benzinga Newsdesk

    Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate

    Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 85 percent increase over losses of $(2.60) per share from

    DMRA